Colorectal cancer secondary prevention

Jump to navigation Jump to search

Colorectal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Colorectal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Metastasis Treatment

Primary Prevention

Secondary Prevention

Follow-up

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Colorectal cancer secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Colorectal cancer secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Colorectal cancer secondary prevention

CDC on Colorectal cancer secondary prevention

Colorectal cancer secondary prevention in the news

Blogs on Colorectal cancer secondary prevention

Directions to Hospitals Treating Colorectal cancer

Risk calculators and risk factors for Colorectal cancer secondary prevention

To view the secondary prevention of familial adenomatous polyposis (FAP), click here
To view the secondary prevention of hereditary nonpolyposis colorectal cancer (HNPCC), click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.

Overview

Secondary prevention of colorectal cancer, as opposed to primary prevention, indicates that a person has already had the disease and there are steps being taken to prevent cancer recurrence, usually as metachronous tumors. This involves annual surveillance with colonoscopy after surgical removal an possibly an adjunct after the initial operation. The timing for secondary prevention is critical to prevent recurrent advanced disease[1].

Colorectal Cancer Secondary Prevention

Familial Colorectal Cancer Syndromes

  • Surgical resection followed by a colonoscopy yearly for most polyposis syndromes[1]
  • Criteria for surveilling patients and categorizing them as polyposis patients include the following[1]:
  • The presence of multiple polyps in the colon
  • Young age at onset of colorectal cancer, particularly age less than 50 years
  • A strong family history suggesting a familial syndrome
  • Evidence for a syndrome based on genetic testing
  • Chemoprevention has been used as an adjunct to colonoscopy in some FAP patients, such as the following:
  • Cyclooxygenase (COX) inhibitors[1]
  • Aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)[2]
  • Postmenopausal hormone therapy (both combined estrogen plus progestin and unopposed estrogen) - not recommended for chemoprevention of colon cancer in women because of the associated long-term risks of therapy[3]

Sporadic Colorectal Cancer Syndromes

  • An individual may develop sporadic colorectal cancer for the following reasons[1]:
  • The patient has an unrecognized familial syndrome
  • The residual tumor may be present after resection
  • The patient has strong risk factors
  • The patient has genetic risk factors that do not fit into a familial syndrome
  • After diagnosis, a colonoscopy should be performed to rule out synchronous tumors and polyps along with a primary tumor resection[1]
  • Within 1 year after the primary tumor resection, another colonoscopy should take place[1]
  • If this examination is negative for lesions, the next colonoscopy generally may be performed after 3 years
  • If that colonoscopy is negative, then secondary prevention by colonoscopy may be extended to every 5 years

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Carethers, John M. (2010). "Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?". Current Colorectal Cancer Reports. 6 (1): 24–29. doi:10.1007/s11888-009-0038-1. ISSN 1556-3790.
  2. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011). "Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials". Lancet. 377 (9759): 31–41. doi:10.1016/S0140-6736(10)62110-1. PMID 21144578. Review in: Ann Intern Med. 2011 Mar 15;154(6):JC3-2 Review in: Evid Based Nurs. 2011 Jul;14(3):71
  3. Lin KJ, Cheung WY, Lai JY, Giovannucci EL (2012). "The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer". Int J Cancer. 130 (2): 419–30. doi:10.1002/ijc.26026. PMID 21365647.


Template:WikiDoc Sources